Clinical Trial Update: Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pyrotinib with capecitabine and bevacizumab for HER2-positive breast cancer with brain metastases; status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer with Brain Metastases

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Tongji Hospital | Conditions: Breast Cancer With Brain Metastases | Phase 2 | Status: UNKNOWN